Brinter

Brinter is a private, pre-revenue biotech firm developing a proprietary 3D bioprinting platform for the mass manufacturing of personalized, regenerative tissue implants. The company's initial pipeline focuses on high-failure-rate orthopedic repairs (e.g., rotator cuff, Achilles tendon, ACL) and aesthetic reconstructions, aiming to improve healing outcomes through biomimetic design and patient-specific biologics. Led by serial entrepreneurs and advised by key orthopedic surgeons, Brinter is positioning itself at the intersection of advanced manufacturing, digital health, and regenerative medicine, with the long-term vision of progressing from orthopedic implants to complex organs.

Patented 3D BioPrinted Tissue platform for scalable mass manufacturing of personalized, regenerative implants. Enables design, biologic, and cellular personalization using biomimetic, bioresorbable materials.

Brinter competes in a nascent but growing field of bioprinting and regenerative medicine. Competition includes other bioprinting startups (e.g., CELLINK/BICO, Aspect Biosystems) and large medtech firms (e.g., Stryker, Johnson & Johnson) investing in regenerative solutions. Brinter's focus on scalable manufacturing for specific clinical applications is a key differentiator.